Aug 8 (Reuters) - Novavax ( NVAX ) reported
second-quarter revenue that was below analysts' estimates on
Thursday due to lower-than-expected sales of its COVID-19
vaccine.
The company recorded $415.5 million in total revenue in the
second quarter, lower than analysts' average estimate of $458.6
million, according to LSEG data.